Gary Liversidge
29Patents
21h-index
35Co-inventors
81Inventor score
Filing activity: Jan 25, 1991 → Feb 6, 2008
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US5145684A | Surface modified drug nanoparticles | Performing Operations; Transporting | 979 | Expired |
| US5399363A | Surface modified anticancer nanoparticles | Performing Operations; Transporting | 451 | Expired |
| US5552160A | Surface modified NSAID nanoparticles | Performing Operations; Transporting | 272 | Expired |
| US5302401A | Method to reduce particle size growth during lyophilization | Human Necessities | 178 | Expired |
| US5580579A | Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers | Emerging Cross-Sectional Technologies | 139 | Expired |
| US5494683A | Surface modified anticancer nanoparticles | Performing Operations; Transporting | 133 | Expired |
| US6045829A | Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers | Performing Operations; Transporting | 124 | Expired |
| US6432381B1 | Methods for targeting drug delivery to the upper and/or lower gastrointestinal tract | Emerging Cross-Sectional Technologies | 107 | Expired |
| US5585108A | Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays | Human Necessities | 106 | Expired |
| US5318767A | X-ray contrast compositions useful in medical imaging | Performing Operations; Transporting | 104 | Expired |
| US5834025A | Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions | Emerging Cross-Sectional Technologies | 84 | Expired |
| US6068858A | Methods of making nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers | Human Necessities | 79 | Expired |
| US6221400A | Methods of treating mammals using nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors | Performing Operations; Transporting | 67 | Expired |
| US5451393A | X-ray contrast compositions useful in medical imaging | Performing Operations; Transporting | 58 | Expired |
| US5466440A | Formulations of oral gastrointestinal diagnostic X-ray contrast agents in combination with pharmaceutically acceptable clays | Performing Operations; Transporting | 56 | Expired |
| US5628981A | Formulations of oral gastrointestinal diagnostic x-ray contrast agents and oral gastrointestinal therapeutic agents | Emerging Cross-Sectional Technologies | 53 | Expired |
| US5593657A | Barium salt formulations stabilized by non-ionic and anionic stabilizers | Emerging Cross-Sectional Technologies | 46 | Expired |
| US8293277B2 | Controlled-release nanoparticulate compositions | Human Necessities | 43 | Expired |
| US7763278B2 | Nanoparticulate polycosanol formulations and novel polycosanol combinations | Human Necessities | 36 | Expired |
| US8623412B2 | Abuse-resistant pharmaceutical compositions | Human Necessities | 24 | Active |
| USRE41884E1 | Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions | General | 24 | Active |
| US7910577B2 | Injectable nanoparticulate olanzapine formulations | Emerging Cross-Sectional Technologies | 21 | Active |
| US8158153B2 | Nanoparticulate bisphosphonate compositions | Human Necessities | 15 | Active |
| US8119163B2 | Nanoparticulate and controlled release compositions comprising cefditoren | Human Necessities | 12 | Active |
| US8003127B2 | Nanoparticulate corticosteroid and antihistamine formulations methods of making, and methods of administering thereof | Emerging Cross-Sectional Technologies | 10 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.